Nonspecific Effects of Oral Polio Vaccine on Diarrheal Burden and Etiology Among Bangladeshi Infants

Alexander Upfill-Brown, Mami Taniuchi, James A Platts-Mills, Beth Kirkpatrick, Stacey L Burgess, M Steven Oberste, William Weldon, Eric Houpt, Rashidul Haque, K Zaman, William A Petri Jr, Alexander Upfill-Brown, Mami Taniuchi, James A Platts-Mills, Beth Kirkpatrick, Stacey L Burgess, M Steven Oberste, William Weldon, Eric Houpt, Rashidul Haque, K Zaman, William A Petri Jr

Abstract

Background: As the global polio eradication initiative prepares to cease use of oral polio vaccine (OPV) in 2020, there is increasing interest in understanding if oral vaccination provides non-specific immunity to other infections so that the consequences of this transition can be effectively planned for and mitigated.

Methods: Data were collected from infants in an urban slum in Bangladesh (Mirpur, Dhaka) as part of the performance of rotavirus and oral polio vaccines in developing countries (PROVIDE) study. Following vaccination with trivalent oral polio vaccine (tOPV) at 6, 10, and 14 weeks, infants were randomly assigned to receive tOPV (n = 315) or inactivated polio vaccine (IPV) (n = 299) at 39 weeks. Episodes of diarrhea were documented through clinic visits and twice-weekly house visits through 52 weeks. In sum, 14 pathogens associated with diarrhea were analyzed with TaqMan Array Cards.

Results: Although the proportion of children experiencing diarrhea was not different between the tOPV and IPV groups (P = .18), the number of days with diarrhea (P = .0037) and the number of separate diarrheal episodes (P = .054) trended lower in the OPV arm. Etiological analysis revealed that male tOPV recipients were less likely to have diarrhea of bacterial etiology (P = .0099) compared to male IPV recipients but equally likely to experience diarrhea due to viruses (P = .57) or protozoa (P = .14). Among the 6 bacterial enteric pathogens tested, only Campylobacter jejuni/coli detection was significantly reduced in the OPV arm (P = .0048).

Conclusions: Our results suggest that OPV may cause nonspecific reductions in mortality, as has been studied elsewhere, by reducing etiology-specific diarrheal burden. This is likely driven by reductions in bacterial diarrhea. Further study of nonspecific OPV effects before global cessation is supported.

Clinical trials registration: NCT01375647.

Keywords: OPV; cross-protection; diarrhea; enteropathogens; vaccines.

© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Cumulative probability of experiencing Shigella/EIEC diarrhea among male infants receiving OPV or IPV at 39 weeks over subsequent 12-week period. Shaded regions represent 95% confidence interval. Abbreviations: EIEC, enteroinvasive E. coli; IPV, inactivated polio vaccine; OPV, oral polio vaccine.

References

    1. Patel M, Orenstein W. A world free of polio—the final steps. N Engl J Med 2016; 374:501–3.
    1. Fish EN, Flanagan KL, Furman D et al. . Changing oral vaccine to inactivated polio vaccine might increase mortality. Lancet 2016; 387:1054–55.
    1. Lund N, Andersen A, Hansen ASK et al. . The effect of oral polio vaccine at birth on infant mortality: a randomized trial. Clin Infec Dis 2015; 61:1504–11.
    1. Biering-Sørensen S, Aaby P, Napirna BM et al. . Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guérin vaccination at first health center contact. Pediatr Infect Dis J 2012; 31:306–8.
    1. Aaby P, Roth A, Ravn H et al. . Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis 2011; 204:245–52.
    1. Aaby P, Martins CL, Garly ML et al. . Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. BMJ 2010; 341:c6495.
    1. Sorup S, Stensballe LG, Krause TG, Aaby P, Benn CS, Ravn H. Oral polio vaccination and hospital admissions with non-polio infections in Denmark: nationwide retrospective cohort study. Open Forum Infect Dis 2015; 3:ofv204.
    1. Netea MG, Joosten LAB, Latz E et al. . Trained immunity: a program of innate immune memory in health and disease. Science 2016; 352:aaf1098.
    1. Benn CS, Netea MG, Selin LK, Aaby P. A small jab—a big effect: nonspecific immunomodulation by vaccines. Trends Immunol 2013; 34:431–9.
    1. Kleinnijenhuis J, Quintin J, Preijers F et al. . Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA 2012; 109: 17537–42.
    1. Jensen KJ, Larsen N, Biering-Sorensen S et al. . Heterologous immunological effects of early BCG vaccination in low-birth weight infants in Guinea-Bissau: a randomized-controlled trial. J Infect Dis 2014; 211:956–67.
    1. Quintin J, Saeed S, Martens JHA et al. . Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 2012; 12:223–32.
    1. Burgess SL, Buonomo E, Carey M et al. . Bone marrow dendritic cells from mice with an altered microbiota provide interleukin 17A-dependent protection against Entamoeba histolytica colitis. mBio 2014; 5:e01817.
    1. Taniuchi M, Platts-Mills JA, Begum S et al. . Impact of enterovirus and other enteric pathogens on oral polio and rotavirus vaccine performance in Bangladeshi infants. Vaccine 2016; 34:3068–75.
    1. Mychaleckyj JC, Haque R, Carmolli M et al. . Effect of substituting IPV for tOPV on immunity to poliovirus in Bangladeshi infants: an open-label randomized controlled trial. Vaccine 2016; 34:358–66.
    1. Kirkpatrick BD, Colgate ER, Mychaleckyj JC et al. . The “Performance of Rotavirus and Oral Polio Vaccines in Developing Countries” (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems. Am J Trop Med Hyg 2015; 92:744–51.
    1. Liu J, Gratz J, Amour C et al. . A laboratory-developed TaqMan array card for simultaneous detection of 19 enteropathogens. J Clin Microbiol 2013; 51:472–80.
    1. Naghavi M, Wang H, Lozano R et al. . Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385:117–71.
    1. Liu J, Platts-Mills JA, Juma J et al. . Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a re-analysis of the GEMS case-control study. Lancet 2016; 388:1291–301.
    1. Muenchhoff M, Goulder PJR. Sex differences in pediatric infectious diseases. J Infect Dis 2014; 209(suppl 3):S120–6.
    1. Noho-Konteh J, Adetifa JU, Cox M et al. . Sex-differential non-vaccine specific immunological effects of diphtheria-tetanus-pertussis and measles vaccination. Clin Infect Dis 2016; 63:1213–26.
    1. Lauterbach H, Kerksiek KM, Busch DH et al. . Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1 protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1. J Virol 2004; 78:4020–28.
    1. Barton ES, White DW, Cathelyn JS et al. . Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 2007; 447:326–29.
    1. Wahid R, Cannon MJ, Chow M. Cytotoxic T-cell responses and long-term T-cell memory in individuals vaccinated against polio virus-specific CD4+ and CD8+ cytotoxic T-cell responses and long-term T-cell memory in individuals vaccinated against polio. J Virol 2005; 79:5988–95.
    1. Janssen R, Krogfelt KA, Cawthraw SA, Van Pelt W, Wagenaar JA, Owen RJ. Host-pathogen interactions in Campylobacter infections: the host perspective. Clin Microbiol Rev 2008; 21:505–18.
    1. Palmer P, Charley B, Rombaut B, Daëron M, Lebon P. Antibody-dependent induction of type I interferons by poliovirus in human mononuclear blood cells requires the type II fcgamma receptor (CD32). Virology 2000; 278(1):86–94.
    1. Klaas M, Oetke C, Lewis LE et al. . Sialoadhesin promotes rapid proinflammatory and type I IFN responses to a sialylated pathogen, Campylobacter jejuni. J Immunol 2012; 189:2414–22.
    1. Colgate ER, Haque R, Dickson DM et al. . Delayed dosing of oral rotavirus vaccine demonstrates decreased risk of rotavirus gastroenteritis associated with serum zinc: a randomized controlled trial. Clin Infect Dis 2016; 63:634–41.
    1. Patel M, Steele AD, Parashar UD. Influence of oral polio vaccines on performance of the monovalent and pentavalent rotavirus vaccines. Vaccine 2012; 30:A30–5.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit